CCDC134抗体;CCDC134 Polyclonal A

Description In extracellular secreted form, promotes proliferation and activation of CD8+ T cells, suggesting a cytokine-like function (PubMed:25125657). Enhances cytotoxic anti-tumor activity of CD8+ T cells (PubMed:25125657). May inhibit ERK and JNK signaling activity (PubMed:18087676, PubMed:23070808). May suppress cell migration and invasion activity, via its effects on ERK and JNK signaling (PubMed:23070808). In the nucleus, enhances stability of the PCAF histone acetyltransferase (HAT) complex member TADA2A and thus promotes PCAF-mediated H3K14 and H4K8 HAT activity. May inhibit TADA2A-mediated TP53/p53 'Lys-321' acetylation, leading to reduced TP53 stability and transcriptional activity. May also promote TADA2A-mediated XRCC6 acetylation thus facilitating cell apoptosis in response to DNA damage. Specification Swissprot:Q9H6E4 WB Predicted band size:27 kDa Host/Isotype:Rabbit IgG Antibody Type:Primary antibody Storage:Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. Species Reactivity:Human, Mouse, Rat Immunogen:Fusion protein of human CCDC134 Formulation:pH7.4 PBS, 0.05% NaN3, 40% Glycerol Application WB:1/1000-1/5000 IHC:1/50-1/200 ELISA:1/5000-1/10000